Amneal Pharmaceuticals, Inc. AMRX Affordable Medicines — Net revenue
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s affordable medicines — net revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s affordable medicines — net revenue?
- Amneal Pharmaceuticals, Inc. (AMRX) reported affordable medicines — net revenue of $423.24M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s affordable medicines — net revenue changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s affordable medicines — net revenue increased by 2.1% year-over-year, from $414.71M to $423.24M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s affordable medicines — net revenue?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s affordable medicines — net revenue has grown at a 6.8% compound annual growth rate (CAGR), from $1.43B to $1.75B.
- What does affordable medicines — net revenue mean?
- Represents the total gross sales generated by the Affordable Medicines segment after accounting for returns, allowances, and rebates. This metric serves as a primary indicator of market demand and commercial success for the company's generic pharmaceutical product portfolio.